Načítá se...
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
PURPOSE: We evaluated the effect of renal impairment (RI) on the pharmacokinetics of telavancin and hydroxypropylbetadex (excipient in the telavancin drug product). METHODS: Adults with normal, mild, moderate or severe RI or end-stage renal disease (ESRD) receiving haemodialysis were included in two...
Uloženo v:
| Vydáno v: | Eur J Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4430595/ https://ncbi.nlm.nih.gov/pubmed/25939708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-015-1847-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|